Literature DB >> 10229135

Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus.

S Jacobsen1, J Petersen, S Ullman, P Junker, A Voss, J M Rasmussen, U Tarp, L H Poulsen, G van Overeem Hansen, B Skaarup, T M Hansen, J Pødenphant, P Halberg.   

Abstract

A multicentre cohort of 513 clinic attenders with systemic lupus erythematosus (SLE) was retrospectively identified, representing 4185 patient-years of follow-up. Expected numbers of death were calculated by means of age- and sex-specific mortality rates of the general Danish population. The observed number of deaths was 122. The survival rates were 97%, 91%, 76%, 64% and 53% after 1, 5, 10, 15, and 20 years respectively. The overall mortality rate was 2.9% per year (95% CI 2.4-3.5), and the standardized mortality rate (SMR) was 4.6 (95% CI 3.8-5.5). The causes of death included active SLE (n = 19), end stage organ failure due to SLE (n = 16), infections (n = 25), malignancy (n = 9), cardiovascular disease (n = 32), and other causes (n = 21). SLE was directly related to one third of the excess mortality. In conclusion, SLE patients in the present cohort had a 4.6-fold increased mortality compared with the general population and half of the deaths were caused by SLE manifestations or infections, especially in young patients during the early period of the disease.

Entities:  

Mesh:

Year:  1999        PMID: 10229135     DOI: 10.1080/030097499442522

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  31 in total

1.  Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus.

Authors:  Aimee O Hersh; Laura Trupin; Jinoos Yazdany; Peter Panopalis; Laura Julian; Patricia Katz; Lindsey A Criswell; Edward Yelin
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-08       Impact factor: 4.794

2.  [Cardiovascular monitoring of patients with systemic lupus erythematosus].

Authors:  H Schotte; H Becker; W Domschke; M Gaubitz
Journal:  Z Rheumatol       Date:  2005-11       Impact factor: 1.372

3.  QT dispersion in patients with systemic lupus erythematosus: the impact of disease activity.

Authors:  Javad Kojuri; Mohammad Ali Nazarinia; Mohammad Ghahartars; Yadollah Mahmoody; Gholam reza Rezaian; Lida Liaghat
Journal:  BMC Cardiovasc Disord       Date:  2012-02-27       Impact factor: 2.298

4.  Plasma ficolin levels and risk of nephritis in Danish patients with systemic lupus erythematosus.

Authors:  Nima Tanha; Katrine Pilely; Mikkel Faurschou; Peter Garred; Søren Jacobsen
Journal:  Clin Rheumatol       Date:  2016-12-15       Impact factor: 2.980

Review 5.  [Changes in mortality and morbidity in systemic lupus erythematosus].

Authors:  G Chehab; R Fischer-Betz; M Schneider
Journal:  Z Rheumatol       Date:  2011-08       Impact factor: 1.372

6.  Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus.

Authors:  Amy H Kao; Christine A McBurney; Abdus Sattar; Apinya Lertratanakul; Nicole L Wilson; Sarah Rutman; Barbara Paul; Jeannine S Navratil; Andrea Scioscia; Joseph M Ahearn; Susan Manzi
Journal:  Transl Stroke Res       Date:  2013-10-27       Impact factor: 6.829

Review 7.  The humanistic and economic burden of systemic lupus erythematosus : a systematic review.

Authors:  Rachel Meacock; Nicola Dale; Mark J Harrison
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

8.  A national study of the complications of lupus in pregnancy.

Authors:  Megan E B Clowse; Margaret Jamison; Evan Myers; Andra H James
Journal:  Am J Obstet Gynecol       Date:  2008-05-05       Impact factor: 8.661

9.  New and emerging treatment approaches to lupus.

Authors:  Marion Haubitz
Journal:  Biologics       Date:  2010-09-13

10.  Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors.

Authors:  Carlos Borelli Zeller; Simone Appenzeller
Journal:  Curr Cardiol Rev       Date:  2008-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.